| Project/Area Number |
25860698
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
MUTO Mayumi 千葉大学, 医学部附属病院, 医員 (10623671)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | 多発性硬化症 / SEREX法 / 発現クローニング / AlphaLISA / バイオマーカー |
|---|
| Outline of Final Research Achievements |
In the pathogenesis of multiple sclerosis (MS), B cell/antibody-related mechanisms have recently received attention. To investigate the role of autoantibody in MS, we performed SEREX which can identify autoantibody cyclopedically. We identified serum antibodies against cytoskeletal protein talin1, and the levels of whom were remarkably higher in 39 MS than 43 normal controls (P <0.01) and 35 disease controls (P=0.06), and in MS patients without oligoclonal bands than ones with them. Moreover, we found the negative-correlations between serum anti-talin1 antibody and IgG index in MS (P =0.03). Anti-talin1 antibody exists in MS patients’ sera, which may have some protective factor.
In addition, we developed "CEREX" using cerebrospinal fluid instead of SEREX using sera, and identified several autoantigens which have a potential to be a biomarker of MS.
|
